Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-01-11

Clinical Trial Update: Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta) [Phase 3]

View source ↗

Summary

Phase 3 trial RoZetta comparing Rituximab versus Zevalin in follicular lymphoma was terminated with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Rituximab (rituximab)
  • Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: Spectrum Pharmaceuticals, Inc | Conditions: Follicular Lymphoma | Phase 3 | Status: TERMINATED | Results posted: 2016-01-11